drugset / Trial / NCT01033071

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

NCT01033071

Phase 3 Completed 1071 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.

Timeline

Start
2010-01
Primary completion
2010-10
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral
Subject Chlorthalidone Other / unclassified 25 mg Oral
Comparator Hydrochlorothiazide Unknown 25 mg Oral
Comparator Olmesartan medoxomil Unknown 40 mg Oral